Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC).
Ing Soo TiongDevendra K HiwaseEmad AbroAshish BajelEmma PalfreymanAshanka BeligaswatteJohn ReynoldsNatasha S AnsteeTamia NguyenSun LooChong Chyn ChuaMichael AshbyKaitlyn M WiltshireShaun FlemingChun Yew FongTse-Chieh TehPiers BlomberyRichard DilonAdam IveyAndrew H WeiPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
For AML in first remission and either MRD or oligoblastic relapse, venetoclax plus LDAC is well tolerated and highly effective.
Keyphrases
- acute myeloid leukemia
- phase ii study
- low dose
- chronic lymphocytic leukemia
- high dose
- free survival
- open label
- locally advanced
- allogeneic hematopoietic stem cell transplantation
- cancer therapy
- disease activity
- rectal cancer
- placebo controlled
- squamous cell carcinoma
- rheumatoid arthritis
- randomized controlled trial
- drug delivery
- single molecule